Clinical Trials
30 trialsNCT05184088 2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3 Completed
NCT05839626 2026-05-27
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Sanofi
Phase 1 Terminated
NCT06963216 2026-05-11
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
Kedrion S.p.A.
Phase 3 Recruiting
NCT05951049 2026-05-06
A Study of AT-02 in Subjects With Systemic Amyloidosis.
Attralus, Inc.
Phase 2 Active not recruiting
NCT07250269 2026-04-28
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1 Recruiting
NCT04512235 2026-04-07
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT07081646 2026-03-24
ALACRITY
Alexion Pharmaceuticals, Inc.
Phase 1/2 Recruiting
NCT04504825 2026-03-17
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT06097832 2025-07-10
NEXICART-2
Nexcella Inc.
Phase 1/2 Recruiting
NCT07055724 2025-07-09
Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis
Nanjing IASO Biotechnology Co., Ltd.
Phase 2 Not yet recruiting
NCT04304144 2025-03-05
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
Alexion Pharmaceuticals, Inc.
Phase 2 Completed
NCT02245867 2025-02-07
Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Alexion Pharmaceuticals, Inc.
Phase 1 Completed
NCT05199337 2024-09-19
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT04659798 2024-07-08
DOrianT
Takeda
Completed
NCT05521022 2024-04-03
AT02-001
Attralus, Inc.
Phase 1 Unknown
NCT02312206 2023-11-14
VITAL
Prothena Biosciences Ltd.
Phase 3 Terminated
NCT05201911 2022-09-15
AT03-001
Attralus, Inc.
Phase 1 Completed
NCT04115956 2022-03-28
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
Oncopeptides AB
Phase 1 Terminated
NCT01318902 2020-04-01
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
Takeda
Phase 1 Completed
NCT02603172 2019-09-23
A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis
GlaxoSmithKline
Phase 1 Terminated
NCT02613182 2019-05-16
OLE
Prothena Biosciences Ltd.
Phase 2 Terminated
NCT02574676 2019-04-09
Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Prothena Biosciences Ltd.
Completed
NCT02632786 2019-04-05
PRONTO
Prothena Biosciences Ltd.
Phase 2 Completed
NCT03154047 2019-03-26
Study in Subjects With Light Chain (AL) Amyloidosis
Prothena Biosciences Ltd.
Phase 2 Terminated
NCT01707264 2018-08-28
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Prothena Biosciences Ltd.
Phase 1/2 Completed
NCT01777243 2018-07-24
A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis
GlaxoSmithKline
Phase 1 Completed
NCT01406314 2017-06-09
SAP Depleter Dose Assessment Study in Patients
GlaxoSmithKline
Phase 1 Completed
NCT02953808 2017-01-19
Phase 1 Study of GSK2315698 in Healthy Japanese Subjects
GlaxoSmithKline
Phase 1 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed